Cereno Scientific

The abstract titled “HDAC inhibitor CS014 inhibits platelet activity, small and large vessel thrombosis while maintaining hemostasis in a dose-dependent manner”, was authored by M. Holinstat, L. Stanger and S. Lambert at the Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, US; B. Dahlöf at the University of Gothenburg, Gothenburg, Sweden; P. Yalavarthi at the Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, US; and, N. Bergh at the University of Gothenburg, Gothenburg, Sweden. The abstract has been selected to be presented as a moderated ePoster presentation by Dr. Michael Holinstat, lead of Cereno’s development programs at the University of Michigan and Director of Translational Research at Cereno.

The abstract titled “CS585 is a novel and highly selective IP receptor agonist for prevention of thrombosis”, was authored by L. Stanger, S. Lambert, A. Yamaguchi, P. Yalavarthi, G. McIntyre, K. Goerger, D. Gilmore, A. Rickenberg and G. Cholack at Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, US; B. Dahlöf and N. Bergh at the University of Gothenburg, Gothenburg, Sweden; and M. Holinstat at the Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, US. The abstract has been selected to be presented as a moderated ePoster presentation by Livia Stanger at the Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, US.

Details on the moderated poster presentation of CS014:

Presentation Title: HDAC inhibitor CS014 inhibits platelet activity, small and large vessel thrombosis while maintaining hemostasis in a dose-dependent manner

Authors: M. Holinstat, L. Stanger and S. Lambert at the Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI; B. Dahlöf at the University of Gothenburg, Gothenburg, Sweden; P. Yalavarthi at the Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI; and, N. Bergh at the University of Gothenburg, Gothenburg, Sweden

Session Title: Current and novel antiplatelet therapy in cardiovascular disease

Presentation Date: Friday, August 25, 2023

Session Time: 17:15 - 18:00 CET

Session Location: Station 9

Details on the moderated poster presentation of CS585:

Presentation Title: Superiority of CS585 as a selective prostacyclin receptor agonist in prevention of thrombosis

Authors: L. Stanger, S. Lambert, A. Yamaguchi, P. Yalavarthi, G. McIntyre, K. Goerger, D. Gilmore, A. Rickenberg and G. Cholack at Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, US; B. Dahlöf and N. Bergh at the University of Gothenburg, Gothenburg, Sweden; and M. Holinstat at the Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, US

Session Title: Current and novel antiplatelet therapy in cardiovascular disease

Presentation Date: Friday, August 25, 2023.

Session Time: 17:15 - 18:00 CET

Session Location: Station 9

For further information, please contact:

Jonas Fogelberg, Interim CFO
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects, selected for prevention of thrombosis as target indication. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Thrombosis prevention in venous or arterial and cardiovascular disease has been selected as the first indication area for CS014. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.